To expand these observations, we must attempt investigating the efficacy of PD-1 or PD-L1 antibodies in various types of canine tumors, and the predictive biomarkers to optimize case/tumor selection, minimize risk of adverse events, and prognosis. Here, PDCD1 is linked to neoplasm.